
The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Unresectable HCC with Extrahepatic Involvement
A 77-Year-Old Male With Unresectable HCC and Extrahepatic Involvement